ReNeuron Group PLC
LSE:RENE
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| UK |
R
|
ReNeuron Group PLC
LSE:RENE
|
1.9m GBP |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
397.7B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.7B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
179.8B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.6B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
86.7B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.5B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -195 650% |
| 30th Percentile | 0% |
| Median | 0.1% |
| 70th Percentile | 0.2% |
| Max | 4 630.7% |
Other Profitability Ratios
ReNeuron Group PLC
Glance View
ReNeuron Group Plc engages in the development of novel cell based therapies that target significant areas of unmet medical need. The company is headquartered in Bridgend, Glamorgan and currently employs 43 full-time employees. The company went IPO on 2005-08-12. The firm develops allogeneic stem cell technology platforms, stem cell derived exosomes and induced pluripotent stem cells. The firm's products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP). The firm's exosomes nanomedicine platform focuses on generating early pre-clinical data in cancer. Its ReNcell Products include ReNcellVM and ReNcellCX cell lines. The company is engaged in Phase II clinical trial of CTX cells for stroke disability. The company is engaged in Phase I clinical trial of CTX cells for Critical Limb Ischaemia. The company is engaged in Phase I clinical trial of hRPC stem cell candidate.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for ReNeuron Group PLC is -2 456%, which is below its 3-year median of -1 899.7%.
Over the last 3 years, ReNeuron Group PLC’s Operating Margin has increased from -20 550% to -2 456%. During this period, it reached a low of -20 550% on Aug 30, 2020 and a high of -1 193.7% on Sep 30, 2022.
